Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
IDO1 encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. Zusätzlich bieten wir Ihnen Indoleamine 2,3-Dioxygenase 1 Kits (16) und Indoleamine 2,3-Dioxygenase 1 Proteine (14) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 177 products:
Human Polyclonal IDO1 Primary Antibody für IF (cc), IF (p) - ABIN1714836
Fu, Zhang, Song, Sheng, Li, Li, Song, Wang, Chu, Wei: Effect of bone marrow-derived CD11b(+)F4/80 (+) immature dendritic cells on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis. in Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2014
Zeige alle 2 Referenzen für ABIN1714836
Human Polyclonal IDO1 Primary Antibody für EIA, FACS - ABIN1107630
Grohmann, Fallarino, Puccetti: Tolerance, DCs and tryptophan: much ado about IDO. in Trends in immunology 2003
Zeige alle 2 Referenzen für ABIN1107630
Human Polyclonal IDO1 Primary Antibody für IHC (p), WB - ABIN389194
Maghzal, Thomas, Hunt, Stocker: Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. in The Journal of biological chemistry 2008
Zeige alle 2 Referenzen für ABIN389194
Human Polyclonal IDO1 Primary Antibody für EIA, IHC (p) - ABIN357869
Scheler, Wenzel, Tüting, Takikawa, Bieber, von Bubnoff: Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? in The American journal of pathology 2007
Zeige alle 2 Referenzen für ABIN357869
Human Polyclonal IDO1 Primary Antibody für IF, IHC - ABIN185488
Munn, Sharma, Baban, Harding, Zhang, Ron, Mellor: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. in Immunity 2005
Mouse (Murine) Polyclonal IDO1 Primary Antibody für IHC (fro), IHC (p) - ABIN1107631
Hill, Pereira, Chauveau, Zagani, Remy, Tesson, Mazal, Ubillos, Brion, Asghar, Ashgar, Mashreghi, Kotsch, Moffett, Doebis, Seifert, Boczkowski, Osinaga, Anegon: Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005
Mouse (Murine) Monoclonal IDO1 Primary Antibody für FACS, IP - ABIN1043734
Mellor, Munn: IDO expression by dendritic cells: tolerance and tryptophan catabolism. in Nature reviews. Immunology 2004
Differential expression of CD25 (zeige IL2RA Antikörper) and IDO mRNA with high and low virulence bovine viral diarrhea virus might reflect temporal differences in transcription during the immune response elicited by these viral strains.
IDO may be involved in downregulating immune responses to M. avium subsp. paratuberculosis and other virulent mycobacteria, which may be an example of the pathogen harnessing host immunoregulatory pathways to aid survival.
INDO participates in IFN-gama-induced death of bovine luteal cells, through a mechanism that involves degradation of tryptophan, thereby reducing tryptophan concentrations to a point insufficient to meet luteal cells needs
SIV-infected macaques exhibiting progression to AIDS displayed greater expression of TGF-beta (zeige TGFB1 Antikörper) and indoleamine 2,3 dioxygenase in CD8 (zeige CD8A Antikörper)+ T cells from mesentric lymph nodes.
IDO gene expression is a feature of aggressive non-muscle-invasive urothelial cell bladder carcinoma, suggesting a potential immunosuppressive role of IDO
Data show that in the absence of indoleamine 2,3-dioxygenase (IDO) inhibition, fatty acid oxidation increased along with increased activity of carnitine palmitoyltransferase I (CPT1 (zeige CPT1A Antikörper)).
High IDO1 expression is associated with cervical cancer.
PSG stimulated IDO activity under the conditions of induction of the monocytes by interferon-gamma (zeige IFNG Antikörper).
These results indicate that the level of IDO expression may be associated with pregnancy-related complications, such as URSA, by affecting trophoblast cell proliferation and migration via the STAT3 (zeige STAT3 Antikörper) signaling pathway.
IDO is a potential prognostic biomarker for overall survival of patients with gastric adenocarcinoma after gastrectomy.
IDO expressed by placenta cells can down-regulate NKp46 (zeige NCR1 Antikörper) and NKG2D (zeige KLRK1 Antikörper) expression and reduce cytotoxicity in NK cells, suggesting an important role for IDO in the maintenance of normal pregnancy
Results suggest that IDO expression is implicated in immunosuppression and tumor progression in glioma cells; combining IDO inhibition with standard TMZ treatment could be an encouraging therapeutic strategy for patients with malignant glioma
Results suggest Withaferin A (WA) as a valuable small ligand molecule with strong binding affinity toward indoleamine 2,3-dioxygenase (IDO).
Our results imply the probability of involvement of IDO in development of tolerance process, and we presume that high IDO activity is associated with nonresponsiveness to food allergens despite allergen sensitization.
this study shows that IDO overexpression in dendritic cells attenuates acute allograft rejection
This insight into IDO1's involvement in pro-tumorigenic inflammatory neovascularization may have important ramifications for IDO1 inhibitor development, not only in cancer where clinical trials are currently ongoing, but in other disease indications associated with neovascularization as well.
Inhibition of IDO activity ameliorated Japanese encephalitis via enhancement of antiviral IFN-I/II innate and adaptive T-cell responses and increased central nervous system infiltration of peripheral leukocytes.
Data show that the expression of indoleamine 2, 3-dioxygenase 1 (IDO) was decreased after tumor cells were infected with Salmonella.
Severity of sodium dodecyl sulfate-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88 (zeige MYD88 Antikörper)-NF-kB transcriptional networks.
IDO1 deficiency does not affect inflammation in Systemic Juvenile Idiopathic Arthritis, Secondary Hemophagocytic Lymphohistiocytosis and a T cell-triggered cytokine release model.
Data indicate that indolamine-2,3-dioxygenase (IDO) and Fibroblast activation protein alpha (zeige FAP Antikörper) (FAPalpha) were detectable in B16 melanoma tumor-bearing mice.
Increased expression of IDO in liver cell adenomas compared to the surrounding normal tissue may create a microenvironment that promotes the progression of HCC (zeige FAM126A Antikörper) by suppressing the proliferation of cytotoxic T lymphocytes and enhancing Tregs.
Chimeric vaccine stimulation of human dendritic cell IDO1 occurs via the non-canonical NF-kappaB (zeige NFKB1 Antikörper) pathway.
This gene encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Through its expression in dendritic cells, monocytes, and macrophages this enzyme modulates T-cell behavior by its peri-cellular catabolization of the essential amino acid tryptophan.
indoleamine-pyrrole 2,3 dioxygenase
, indoleamine 2,3-dioxygenase 2
, putative indoleamine 2,3-dioxygenase
, indoleamine 2,3-dioxygenase 1
, indolamine 2,3 dioxygenase
, indole 2,3-dioxygenase
, indoleamine-pyrrole 2,3-dioxygenase
, indoleamine 23-dioxygenase